Intellicell Biosciences announces the licensing of its proprietary patent, pending stromal vascular fraction manufacturing

The Company licensed the technology for Australia & New Zealand for a one-time payment offer $700,000 and 12 1/2% Royalty Stream

NEW YORK--(BUSINESS WIRE)-- Intellicell Biosciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC); (“Intellicell”) or the (“Company”), Intellicell has licensed its proprietary, patent, pending technology for the manufacture of stromal vascular fraction from adipose tissue to Cell-Innovations, Pty Limited a company headquartered in Sydney, Australia. The license calls for a one-time payment of $700,000 and a royalty stream of 12 ½ % of net of sales.

Intellicell’s process is a patent-pending non-enzymatic method for deriving stromal vascular fraction from 60cc’s of adipose tissue. This process dramatically increases the yield in manufacturing stromal vascular fraction compared to the present enzymatic methods in use today. Intellicell’s process generates between half billion - 1.4 billion SVFC cells from 60 ccs from a patient’s own adipose tissue. This is approximately 10-20 times greater than enzyme based methods. Dr. Steven Victor, CEO, said “we are extremely excited about our licensing partnership with Cell-Innovations, Inc. We believe they are one of the best positioned companies to market the Intellicell technology in Australia & New Zealand.

Cell-Innovations is an Australian company headquartered in Sydney servicing the burgeoning regenerative medicine market by providing innovative IntelliCell technology to the Australian and New Zealand marketplace. We believe that IntelliCell technology will be a “game-changer” in the regenerative medicine field making available stromal vascular fraction (SVF) treatment to the public. Cell-Innovations CEO is Dr. Wayne Thomas BSc PhD a founder of Australian Cell Technologies, a company introducing regenerative cellular products to the veterinary market. Dr. Thomas has 25 years experience in cell biology and developed kits for adipose SVF for the veterinary market. Dr. Thomas’ research contributions has been recognized by many publications and book chapters, and is a reviewer for both national and international granting bodies and journals; and, will be a scientific advisor for IntelliCell. Dr Ralph Bright MB ChB FFMACC is a director with Cell-Innovations and is a pioneer in stromal vascular fraction treatments in Australia, a Fellow and Member of many cosmetic medicine organizations including the Cosmetic Physicians Society of Australasia and the Australian College of Cosmetic Surgery. Dr Bright has been treating patients with adipose SVF since 2009 for osteoarthritis and degenerative neurological disease and is one of the most experienced physicians in Australia in the use of adipose SVF. “Cell-Innovations and IntelliCell will assist Macquarie Stem Cells to establish ‘Intellicell Centers of Excellence’ where doctors can treat their patient”

About IntelliCell BioSciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients. The company is also setting upCenters of Excellence where doctors can treat their patients. In addition, IntelliCell BioScience in exploring storing the stromal vascular fraction in cryostorage for future uses. The company is also starting FDA IND clinical trials at major medical centers for clinical indication approval. IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212-249-3050.



CONTACT:

Investor Relations for IntelliCell BioSciences Inc.
Laurel Moody, 646-810-0608

KEYWORDS:   Australia  United States  North America  Australia/Oceania  New Zealand  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Medical Devices  Other Health  Manufacturing  Other Manufacturing

MEDIA:

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.